Passage Bio, Inc. (PASG)
4.65
-0.10
(-2.11%)
USD |
NASDAQ |
Sep 04, 16:00
4.68
+0.03
(+0.65%)
After-Hours: 20:00
Passage Bio Research and Development Expense (Quarterly) : 3.343M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 3.343M |
| March 31, 2026 | 4.093M |
| December 31, 2025 | 5.418M |
| September 30, 2025 | 4.307M |
| June 30, 2025 | 5.814M |
| March 31, 2025 | 7.737M |
| December 31, 2024 | 9.558M |
| September 30, 2024 | 8.656M |
| June 30, 2024 | 10.43M |
| March 31, 2024 | 11.54M |
| December 31, 2023 | 12.16M |
| September 30, 2023 | 13.70M |
| June 30, 2023 | 17.32M |
| March 31, 2023 | 16.84M |
| December 31, 2022 | 17.66M |
| September 30, 2022 | 15.36M |
| Date | Value |
|---|---|
| June 30, 2022 | 26.82M |
| March 31, 2022 | 26.21M |
| December 31, 2021 | 32.97M |
| September 30, 2021 | 26.62M |
| June 30, 2021 | 33.11M |
| March 31, 2021 | 24.97M |
| December 31, 2020 | 27.93M |
| September 30, 2020 | 20.84M |
| June 30, 2020 | 19.90M |
| March 31, 2020 | 13.12M |
| December 31, 2019 | 9.973M |
| September 30, 2019 | 10.43M |
| June 30, 2019 | 6.299M |
| March 31, 2019 | 3.033M |
| December 31, 2018 | 5.941M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| ARS Pharmaceuticals, Inc. | 4.698M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |
| Anika Therapeutics, Inc. | 7.341M |
| Savara, Inc. | 21.95M |